DePuy’s Faulty Hip Replacement Shadow Lingers As India Issues Recall
This article was originally published in PharmAsia News
Executive Summary
The device manufacturer is under increasing regulatory pressure on the measures it took to inform patients or reimburse for tests and revision surgeries.
You may also be interested in...
News Briefs: DePuy ASR Settlement; Tandem Diabetes IPO; AtriCure Trial
DePuy settles bulk of U.S. ASR suits. Tandem Diabetes closes $138 million IPO. AtriCure gets go-ahead for new AtriClip stroke. More news.
J&J/DePuy Recalls ASR Hip Systems - Effort Could Cost $1.2 Bil.
Johnson & Johnson subsidiary DePuy Orthopaedics is recalling all of its ASR hip resurfacing and ASR XL acetabular hip replacement systems worldwide due to elevated rates of revision surgeries to replace the devices, the company said Aug. 26
Indian Investors Turn Cautious On Compliance Concerns
A rising number of enforcement actions by major drug regulators like the U.S. FDA is slowly making investors cautious about the longer term repercussions on earnings of Indian drug makers.